These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11818178)

  • 1. Impact of the U.S. panel on cost-effectiveness in health and medicine.
    Phillips KA; Chen JL
    Am J Prev Med; 2002 Feb; 22(2):98-105. PubMed ID: 11818178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
    Russell LB; Gold MR; Siegel JE; Daniels N; Weinstein MC
    JAMA; 1996 Oct; 276(14):1172-7. PubMed ID: 8827972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.
    Meltzer D; Johannesson M
    Med Decis Making; 1999; 19(4):371-7. PubMed ID: 10520672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine: A Reference, Not a Rule Book.
    Carias C; Chesson HW; Grosse SD; Li R; Meltzer MI; Miller GF; Murphy LB; Nurmagambetov TA; Pike JJ; Whitham HK
    Am J Prev Med; 2018 Apr; 54(4):600-602. PubMed ID: 29338958
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
    Weinstein MC; Siegel JE; Gold MR; Kamlet MS; Russell LB
    JAMA; 1996 Oct; 276(15):1253-8. PubMed ID: 8849754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of patient preferences for comorbidities in cost-effectiveness analyses.
    Harris RA; Nease RF
    J Health Econ; 1997 Feb; 16(1):113-9. PubMed ID: 10167342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies.
    Joore M; Brunenberg D; Nelemans P; Wouters E; Kuijpers P; Honig A; Willems D; de Leeuw P; Severens J; Boonen A
    Value Health; 2010; 13(2):222-9. PubMed ID: 19878492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction.
    Kuntz KM; Tsevat J; Weinstein MC; Goldman L
    JAMA; 1999 Dec; 282(23):2246-51. PubMed ID: 10605977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are methods for estimating QALYs in cost-effectiveness analyses improving?
    Neumann PJ; Zinner DE; Wright JC
    Med Decis Making; 1997; 17(4):402-8. PubMed ID: 9343798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls.
    Bambha K; Kim WR
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):519-26. PubMed ID: 15167152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.
    Siegel JE; Weinstein MC; Russell LB; Gold MR
    JAMA; 1996 Oct 23-30; 276(16):1339-41. PubMed ID: 8861994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine.
    Paulden M; O'Mahony JF; McCabe C
    Pharmacoeconomics; 2017 Jan; 35(1):5-13. PubMed ID: 27943173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for future costs in medical cost-effectiveness analysis.
    Meltzer D
    J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental cost-effectiveness of adult spinal deformity surgery: observed quality-adjusted life years with surgery compared with predicted quality-adjusted life years without surgery.
    McCarthy I; O'Brien M; Ames C; Robinson C; Errico T; Polly DW; Hostin R;
    Neurosurg Focus; 2014 May; 36(5):E3. PubMed ID: 24785485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth and quality of the cost-utility literature, 1976-2001.
    Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
    Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.
    Siegel JE; Torrance GW; Russell LB; Luce BR; Weinstein MC; Gold MR
    Pharmacoeconomics; 1997 Feb; 11(2):159-68. PubMed ID: 10172935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.